永顺生物
(839729)
| 流通市值：8.13亿 | | | 总市值：28.92亿 |
| 流通股本：7682.50万 | | | 总股本：2.73亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 35,746,237.2 | 33,786,224.75 | 205,984,757.13 | 161,395,328.66 |
| 应收票据及应收账款 | 113,425,944.75 | 106,604,358.75 | 107,977,565.45 | 116,017,831.12 |
| 其中：应收票据 | 9,485,275.58 | 15,082,881.91 | 13,408,415.33 | 14,613,285.7 |
| 应收账款 | 103,940,669.17 | 91,521,476.84 | 94,569,150.12 | 101,404,545.42 |
| 应收款项融资 | 724,580 | - | 3,283,790 | 3,283,790 |
| 预付款项 | 89,629.5 | 250,215.63 | 186,862.42 | 862,322 |
| 其他应收款合计 | 2,370,437.65 | 2,652,049.47 | 2,124,299.08 | 1,888,780.12 |
| 存货 | 29,472,052.05 | 38,619,478.7 | 41,366,432.72 | 41,281,158.78 |
| 其他流动资产 | 401,846,947.89 | 328,100,861.1 | 203,369,520.26 | 202,086,913.62 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 583,675,829.04 | 559,004,905.13 | 584,482,912.07 | 563,546,980.74 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 150,000 | 150,000 | 150,000 | 150,000 |
| 固定资产 | 173,148,832.65 | 180,468,062.67 | 187,963,269.75 | 193,992,689.95 |
| 在建工程 | 7,340,816.84 | 7,403,231.84 | 7,403,231.84 | 8,039,471.84 |
| 使用权资产 | 1,150,044.32 | 1,286,714.9 | 1,424,152.88 | 1,562,358.26 |
| 无形资产 | 14,646,933.35 | 5,121,150.03 | 5,253,700.02 | 5,386,250.01 |
| 长期待摊费用 | 298,245.44 | 334,034.93 | 369,824.42 | 405,613.91 |
| 递延所得税资产 | 107,034.24 | 744,964.73 | - | - |
| 其他非流动资产 | 7,284,400 | 14,835,200 | 14,818,917.25 | 14,776,600 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 204,126,306.84 | 210,343,359.1 | 217,383,096.16 | 224,312,983.97 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 787,802,135.88 | 769,348,264.23 | 801,866,008.23 | 787,859,964.71 |
| 流动负债: | | | | |
| 短期借款 | 27,941,220.65 | 32,595,520.17 | 27,388,015.75 | 19,401,038.96 |
| 应付票据及应付账款 | 67,702,730.04 | 57,510,681.82 | 56,307,418.7 | 46,539,069.87 |
| 应付账款 | 67,702,730.04 | 57,510,681.82 | 56,307,418.7 | 46,539,069.87 |
| 合同负债 | 21,829,351.97 | 25,593,406.17 | 23,048,399.13 | 29,749,589.94 |
| 应付职工薪酬 | 5,258,007.64 | 2,036,361.84 | 3,220,737.51 | 7,812,287.88 |
| 应交税费 | 2,938,891.45 | 2,275,735.56 | 1,167,329.36 | 889,292.93 |
| 其他应付款合计 | 2,677,329.79 | 2,505,503.93 | 2,347,846 | 2,583,065.73 |
| 一年内到期的非流动负债 | 583,681.08 | 574,078.46 | 564,590.13 | 554,997.68 |
| 其他流动负债 | 428,320.46 | 548,052.18 | 438,541.54 | 704,237.74 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 129,359,533.08 | 123,639,340.13 | 114,482,878.12 | 108,233,580.73 |
| 非流动负债: | | | | |
| 租赁负债 | 662,317.29 | 808,728.3 | 963,058.81 | 1,105,969.58 |
| 递延收益 | 8,821,650 | 9,371,132.07 | 9,267,508.58 | 9,873,694.84 |
| 递延所得税负债 | - | - | 227,885.89 | 96,554.24 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 9,483,967.29 | 10,179,860.37 | 10,458,453.28 | 11,076,218.66 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 138,843,500.37 | 133,819,200.5 | 124,941,331.4 | 119,309,799.39 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 273,350,000 | 273,350,000 | 273,350,000 | 273,350,000 |
| 资本公积 | 222,590,227.52 | 222,590,227.52 | 222,590,227.52 | 222,590,227.52 |
| 减:库存股 | 28,821,193.58 | 28,821,193.58 | 28,821,193.58 | 28,821,193.58 |
| 盈余公积 | 64,918,823.11 | 64,918,823.11 | 64,918,823.11 | 64,918,823.11 |
| 未分配利润 | 116,920,778.46 | 103,491,206.68 | 144,886,819.78 | 136,512,308.27 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 648,958,635.51 | 635,529,063.73 | 676,924,676.83 | 668,550,165.32 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 648,958,635.51 | 635,529,063.73 | 676,924,676.83 | 668,550,165.32 |
| 负债和股东权益合计 | 787,802,135.88 | 769,348,264.23 | 801,866,008.23 | 787,859,964.71 |
| 公告日期 | 2024-10-25 | 2024-08-16 | 2024-04-29 | 2024-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |